SecBot SecBot

BCRX drug pipeline

$7.45
−2.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±0.4%
1-day, median of 5 events
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 3
Time to marketAssuming positive Phase 3 data (Q3 2027), a US regulatory filing would follow around end-2027, with potential approval in 2028-2029.

navenibart Updated Jul 3

What to watch

Navenibart is a promising long-term pipeline story within BioCryst, but there is no imminent binary catalyst for ~12+ months. Investors should watch for interim data updates at medical conferences and the pivotal Phase 3 ALPHA-ORBIT readout in Q3 2027. In the meantime, near-term BCRX value is driven by ORLADEYO commercial execution and the ongoing business restructuring.

Bull case
  • Potentially best-in-class dosing convenience, every 3 or 6 months vs. every 2 weeks (Takhzyro) or daily (ORLADEYO), a strong differentiation in the HAE market.
  • Positive Phase 1b/2 ALPHA-STAR data showed meaningful reductions in HAE attack frequency and severity with a clean safety profile across 29 patients.
  • BioCryst already has a proven HAE commercial infrastructure (ORLADEYO in ~$625-645M/year revenue), positioning it well to launch navenibart with existing prescriber and payer relationships.
Bear case
  • Phase 3 topline data not expected until Q3 2027, a ~12-15 month wait with no near-term binary catalyst for the stock.
  • Crowded and competitive HAE prophylaxis market includes Takeda's Takhzyro (lanadelumab, approved 2018), Ionis' newly approved Dawnzera (donidalorsen, approved Sept 2025), CSL's Haegarda, and BioCryst's own ORLADEYO, all targeting the same patient pool.
  • As an injectable biologic, navenibart competes against BioCryst's own oral drug ORLADEYO, potential for internal cannibalization.
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercialized (Dec 2020 adult capsules; Dec 2025 pediatric oral pellets)

ORLADEYO berotralstat Updated Jul 3

What to watch

ORLADEYO is the sole commercial driver of BCRX stock. Watch quarterly ORLADEYO sales growth trajectory (2026 guidance $625M-$645M), pediatric pellet launch uptake, and competitive dynamics vs. Takhzyro and new injectable entrants. The company achieved its first annual profit in 2025, a significant de-risking milestone. The next major pipeline catalyst for the stock overall is the Phase 3 ALPHA-ORBIT navenibart readout, which could expand the HAE franchise.

Bull case
  • ORLADEYO is the only once-daily oral preventative for HAE, offering a clear convenience advantage over injectable competitors like Takeda's Takhzyro, a meaningful differentiator in a chronic-disease market.
  • Revenue grew 38% YoY to $601.8M in 2025, and the company achieved its first full-year GAAP profitability, a major de-risking milestone.
  • The December 2025 pediatric oral pellet approval opens a new patient segment (ages 2 to <12), expanding the addressable market with no direct oral competition.
Bear case
  • Takhzyro (lanadelumab, Takeda) is more efficacious (~90% attack reduction vs. ORLADEYO's ~50-70% reduction) and is the market leader, ORLADEYO competes on convenience, not superior efficacy.
  • The HAE market is seeing new injectable entrants that could intensify competition and pressure ORLADEYO's market share over time.
  • Short interest was elevated on multiple days in late June 2026, suggesting persistent bearish positioning.
● neutral
Impact
PhasePhase 1/1b
Time to marketLikely 5+ years, if successful. Currently in Phase 1/1b with proof-of-concept data expected end of 2026. Netherton syndrome is an ultra-rare disease, which could support an accelerated development path, but the program is still very early.

BCX17725 Updated Jul 3

What to watch

BCX17725 is too early-stage to move the needle for BCRX on its own. The stock's primary catalysts are ORLADEYO revenue growth and navenibart Phase 3 data (Q3 2027). Watch for BCX17725 proof-of-concept data by year-end 2026 as a potential pipeline-validation signal, but do not size a position around it.

Bull case
  • Netherton syndrome is an ultra-rare, severe skin disease with NO approved targeted therapies, BCX17725 addresses a clear unmet need and faces no directly approved competition.
  • KLK5 inhibition targets the underlying pathophysiology of Netherton syndrome (overactive serine protease in the skin), offering a disease-modifying approach rather than just symptom management.
  • Biopharma Watch and DelveInsight list BCX17725 as a leading pipeline drug for Netherton syndrome, alongside only a handful of competitors (QRX003 from Quoin Pharma, ATR-12 from Azitra).
Bear case
  • BCX17725 is in Phase 1/1b, historically, more than 90% of Phase 1 drugs fail to reach approval. Early safety/efficacy data from just 12 patients will be highly preliminary.
  • The drug is a protein therapeutic (BioCryst's first), introducing manufacturing, delivery, and immunogenicity risks that are novel for the company.
  • Competitor QRX003 (Quoin Pharmaceuticals) already has Orphan Drug Designation in the US, EU, and Japan, plus Fast Track and Rare Pediatric Disease designations from the FDA, and is planning a pivotal Phase 3 study, potentially beating BCX17725 to market.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

5 events
DateDrugEvent1 day5 days
Dec 12, 2025ORLADEYOApproval+0.1%−2.2%
Dec 11, 2025ORLADEYOApproval−1.2%−4.8%
Dec 1, 2025ORLADEYOApproval−0.3%+7.2%
Dec 3, 2020ORLADEYOApproval+21.0%+51.8%
Dec 19, 2014RAPIVABApproval+0.4%+12.2%

Clinical trials

4 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
BCX9930 monotherapyBCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor TherapyPhase 2Terminated · results12Sep 18, 2023
EculizumabBCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyPhase 2Terminated · results12Sep 14, 2023
EQ001A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHDPhase 2Completed · results30Nov 21, 2022
BCX9930Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)Phase 2Terminated · results2Sep 23, 2022